Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
4.810
+0.260 (5.71%)
Aug 7, 2026, 4:00 PM EDT - Market closed
Lexeo Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 71.77 | 63 | 35.01 | 121.47 | 77.34 | 135.86 |
Short-Term Investments | 121.28 | 118.77 | 86.5 | - | - | - |
Cash & Short-Term Investments | 193.04 | 181.77 | 121.52 | 121.47 | 77.34 | 135.86 |
Cash Growth | 93.37% | 49.58% | 0.04% | 57.06% | -43.08% | 362.53% |
Other Current Assets | 7.82 | 6.63 | 4.6 | 2.83 | 2.71 | 0.82 |
Total Current Assets | 200.86 | 188.39 | 126.12 | 124.29 | 80.05 | 136.68 |
Net Property, Plant & Equipment | 8.35 | 8.86 | 10.56 | 12.26 | 13.78 | 0.17 |
Long-Term Investments | 37.9 | 68.19 | 7.01 | - | - | - |
Other Long-Term Assets | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 | 0 |
Total Assets | 250.36 | 268.69 | 146.94 | 139.81 | 97.08 | 136.86 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 3.34 | 4.86 | 6.42 | 3.79 | 2.68 | 3.06 |
Accrued Expenses | 8.16 | 9.28 | 13.76 | 10.84 | 8.33 | 3.81 |
Current Portion of Leases | 2.7 | 2.68 | 2.67 | 2.61 | 2.83 | - |
Unearned Revenue | - | - | - | - | - | 0.05 |
Other Current Liabilities | - | - | - | - | 0.51 | 0.53 |
Total Current Liabilities | 14.19 | 16.81 | 22.85 | 17.24 | 14.35 | 7.45 |
Long-Term Leases | 4.67 | 5.21 | 7.25 | 9.03 | 10.65 | - |
Total Long-Term Liabilities | 4.67 | 5.21 | 7.25 | 9.03 | 10.65 | - |
Total Liabilities | 18.86 | 22.02 | 30.1 | 26.27 | 25 | 7.45 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.01 | 0.01 | 0 | 0 | - | - |
Treasury Stock | -0.02 | -0.02 | -0.02 | - | - | - |
Additional Paid-in Capital | 631.98 | 626.63 | 397.13 | 295.37 | 2.49 | 0.57 |
Accumulated Other Comprehensive Income | -0.14 | 0.19 | -0.1 | - | - | - |
Retained Earnings | -400.33 | -380.13 | -280.17 | -181.84 | -115.45 | -56.17 |
Total Common Shareholders' Equity | 231.5 | 246.67 | 116.84 | 113.54 | -112.95 | -55.6 |
Minority Interest | - | - | - | - | 185.03 | 185.01 |
Shareholders' Equity | 231.5 | 246.67 | 116.84 | 113.54 | 72.08 | 129.41 |
Total Liabilities & Equity | 250.36 | 268.69 | 146.94 | 139.81 | 97.08 | 136.86 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 7.37 | 7.89 | 9.92 | 11.64 | 13.48 | 0 |
Net Cash (Debt) | 185.68 | 173.88 | 111.59 | 109.83 | 63.85 | 135.86 |
Net Cash Growth | 105.32% | 55.82% | 1.61% | 72.00% | -53.00% | 362.53% |
Net Cash Per Share | 2.83 | 3.24 | 3.51 | 20.51 | 39.16 | 87.50 |
Book Value | 231.5 | 246.67 | 116.84 | 113.54 | -112.95 | -55.6 |
Book Value Per Share | 3.53 | 4.60 | 3.68 | 21.20 | -69.28 | -35.81 |
Tangible Book Value | 231.5 | 246.67 | 116.84 | 113.54 | -112.95 | -55.6 |
Tangible Book Value Per Share | 3.53 | 4.60 | 3.68 | 21.20 | -69.28 | -35.81 |